CN119343375A - 抗腺苷受体(a2ra)抗体及其用途 - Google Patents

抗腺苷受体(a2ra)抗体及其用途 Download PDF

Info

Publication number
CN119343375A
CN119343375A CN202380044238.1A CN202380044238A CN119343375A CN 119343375 A CN119343375 A CN 119343375A CN 202380044238 A CN202380044238 A CN 202380044238A CN 119343375 A CN119343375 A CN 119343375A
Authority
CN
China
Prior art keywords
ext
seq
amino acid
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380044238.1A
Other languages
English (en)
Chinese (zh)
Inventor
赵新燕
胡昌云
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anpu Biomedical Technology Shenzhen Co ltd
Andetai Pharmaceutical Co ltd
Original Assignee
Anpu Biomedical Technology Shenzhen Co ltd
Andetai Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anpu Biomedical Technology Shenzhen Co ltd, Andetai Pharmaceutical Co ltd filed Critical Anpu Biomedical Technology Shenzhen Co ltd
Publication of CN119343375A publication Critical patent/CN119343375A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380044238.1A 2022-03-30 2023-03-30 抗腺苷受体(a2ra)抗体及其用途 Pending CN119343375A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263325578P 2022-03-30 2022-03-30
US63/325578 2022-03-30
PCT/US2023/016917 WO2023192489A2 (en) 2022-03-30 2023-03-30 Anti-adenosine receptor (a2ar) antibodies and the use thereof

Publications (1)

Publication Number Publication Date
CN119343375A true CN119343375A (zh) 2025-01-21

Family

ID=88203254

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380044238.1A Pending CN119343375A (zh) 2022-03-30 2023-03-30 抗腺苷受体(a2ra)抗体及其用途

Country Status (5)

Country Link
US (1) US20250206828A1 (https=)
EP (1) EP4499702A2 (https=)
JP (1) JP2025511270A (https=)
CN (1) CN119343375A (https=)
WO (1) WO2023192489A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025257365A1 (en) 2024-06-14 2025-12-18 Institut National de la Santé et de la Recherche Médicale Adenosine a2a antagonists for the treatment of endometriosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI560199B (en) * 2010-08-31 2016-12-01 Sanofi Sa Peptide or peptide complex binding to α2 integrin and methods and uses involving the same
JP2023540339A (ja) * 2020-09-04 2023-09-22 インパクト バイオ ユーエスエー インコーポレイテッド 癌治療に使用するためのバイシストロン性阻害性キメラ抗原受容体（ｉＣＡＲ）／活性化キメラ抗原受容体（ａＣＡＲ）構築物

Also Published As

Publication number Publication date
JP2025511270A (ja) 2025-04-15
WO2023192489A2 (en) 2023-10-05
WO2023192489A3 (en) 2024-01-04
EP4499702A2 (en) 2025-02-05
WO2023192489A8 (en) 2024-08-15
US20250206828A1 (en) 2025-06-26

Similar Documents

Publication Publication Date Title
US12350333B2 (en) Checkpoint regulator antagonists
US20250361306A1 (en) Antitumor immune checkpoint regulator antagonists
CN114340735B (zh) 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
US20230340132A1 (en) ANTI-ADENOSINE RECEPTOR (A2aR) ANTIBODIES
US20250206828A1 (en) ANTI-ADENOSINE RECEPTOR (A2aR) ANTIBODIES AND THE USE THEREOF
JP2025511270A5 (https=)
US20250171542A1 (en) Anti-programmed death-ligand 1 (pd-l1) antibodies
HK40124840A (zh) 抗腺苷受体(a2ra)抗体及其用途
WO2023192289A2 (en) Anti-trophoblast cell surface antigen 2 (trop-2) antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40124840

Country of ref document: HK